BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200204
DTEND;VALUE=DATE:20200206
DTSTAMP:20260515T051658
CREATED:20191002T082938Z
LAST-MODIFIED:20191002T082938Z
UID:22661-1580774400-1580947199@www.pharmajournalist.com
SUMMARY:Parallel Trade 2020
DESCRIPTION:Exploring the dynamics\, legalities and hurdles in a period of transition for Parallel Trade \nSMi presents Europe’s leading 14th annual Parallel Trade conference\, taking place in London on the 4th-5th of February 2020. As the only B2B parallel trade conference in Europe\, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade. \nThe size of the EU market in pharmaceutical distribution is around €5bn\, and the UK accounts for 22.7% of this figure. The sector has an annual import value of around £1bn\, while the annual export figure approximates £600m. \nThe 2020 event will hold a particular place of significance on shortages of medicines\, current and ongoing challenges posed by Parallel Trading\, potential implications of Brexit and IP exhaustion rights. \nFurthermore\, the FMD (Falsified Medicines Directive) will be coming into effect in February 2020. This conference will give companies affected the perfect opportunity to discuss and consider the impact that the FMD implementation will have on their practices and on the market. \nThe benefits of attending: \nThis conference is a must-attend show for anyone involved in the parallel trade industry within pharmaceuticals and life sciences. Attending the show gives you the chance to interact with and discuss common issues with leaders involved in all the areas of the parallel trade industry. Furthermore\, this provides core information to further strengthen your industry knowledge and approaches. \n\nAssessing the economic impact and dynamics of Parallel Trade\nReviewing how to overcome the challenges and hurdles in Parallel Trade\nUnderstanding the underlying principles of the EU internal market and competition policies\nDiscussing the impact of Parallel trade on patient safety\nWhat’s the impact and consequences of a no deal Brexit on testing and clinical trials?\nImpact on shortages\, availability\, accessibility and innovation\nAssessing current EU legislative instruments and changes in IP framework\nAn update on current illegal trade cases and the Falsified Medicines Directive\n\nEARLY-BIRD RATES: \n\nBOOK BY 31st OCTOBER AND SAVE £400\nBOOK BY 29th NOVEMBER AND SAVE £200\nBOOK BY 13th DECEMBER AND SAVE £100\n\nPlus two pre-conference interactive workshops  \nWorkshop A : Parallel Trade and Brexit… Where are we now?\nTushar Patel\, Principal Consultant\, Key Pharmaceuticals Ltd \nWorkshop B: Understanding IP\, regulatory and competition law issues in pharmaceutical parallel trade\nJohn Schmidt\, Partner\, Antitrust\, Arnold & Porter Kaye Scholer \nAdditional Contact Info: \nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk \nLinkedIn: @SMi Pharma\nTwitter: @SMiPharm #SMi #SMiParallel
URL:https://www.pharmajournalist.com/event/parallel-trade-2020/
LOCATION:Holiday Inn\, Kensington Forum 97 Cromwell Rd\, Kensington\, London SW7 4DN\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200204
DTEND;VALUE=DATE:20200206
DTSTAMP:20260515T051658
CREATED:20200109T073947Z
LAST-MODIFIED:20200109T073947Z
UID:23578-1580774400-1580947199@www.pharmajournalist.com
SUMMARY:Smartlab Exchange USA
DESCRIPTION:The Smartlab Exchange is an invitation-only meeting bringing together 70 of the most senior lab leaders from across the world\, plus a number of hand-selected solution providers for two days of one-to-one business meetings\, benchmarking\, discussions and networking. \n \nKey themes include: \n✓ Devising a Roadmap to Success for an Agile\, Adaptable\, Digitized Lab\n✓ Harnessing Lab Automation Strategies\n✓ Leverage Big Data Analytics and Informatics\n✓ Augmenting Existing Systems/Processes with Emerging Technologies\n✓ Implementing Methods to Safeguard Data Integrity and Uphold Regulatory Compliance \n96% of our attendees would recommend our event \n“I got more out of one day at Smartlab than a normal day at another conference.” –  R&D IS Program Manager\, Biomerieux \nBelow are some of the 20+ presentations and interactive sessions we have in store: \n\nAbbvie – Transforming The R&D Lab: What It Takes\nIDC – Leveraging AI To Supercharge Data and Analysis Efficiencies In The Connected Lab\nPepsico – Blending Technology\, Process and Digitization To Enable Smart Data-Driven Lab Transformation\nJohnson & Johnson – The Digital Patient & Consumer In Healthcare\n\nCheck out the full agenda here: http://bit.ly/35z1F5m
URL:https://www.pharmajournalist.com/event/smartlab-exchange-usa/
LOCATION:Hilton Fort Lauderdale Marina\, FL\, United States
ORGANIZER;CN="IQPC":MAILTO:info@exchangeevents.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200206
DTEND;VALUE=DATE:20200208
DTSTAMP:20260515T051658
CREATED:20191031T095454Z
LAST-MODIFIED:20191031T104545Z
UID:23112-1580947200-1581119999@www.pharmajournalist.com
SUMMARY:4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference
DESCRIPTION:Since our past editions we dedicated our focus on the latest developments and addressed various applications of CRISPR as a molecular tool\, gene expression\, knock-in\, genomic screening\, along with therapeutic developments through animal modeling. Attended by 100+ genome editing professionals and 20+ gene expert speakers\, the event saw participation of big companies like Casebia Therapeutics\, Genentech\, BMS\, Cellectis \, University of Laval\, University of California\, Center of Advanced Genome Engineering\, Georgia Tech\, Stanford University\, Locana\, Harvard Medical School\, Agility\, Poseida\, Vertex\, Ligandal\, Integrated DNA Technologies\, GE Healthcare\, Cellecta\, Agilent\, Advanced Analytical\, Thermofisher\, Atum\, Synthego\, New England Biolabs\, Aldevron\, Applied Stem Cell and more. \n \nIn 2020\, coming with the 4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference on 6th & 7th February in San Diego\, we are getting ahead by discussing the commercialization and advancements of technology which will outline breakthrough advancements in pre-clinical & clinical therapeutics using genome Editing. The event will also focus on analysis of off target effects\, specificity and aspects of gene and cellular therapies. \nTo learn more about 4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference click here
URL:https://www.pharmajournalist.com/event/4th-edition-marketsandmarkets-genome-editing-gene-therapy-conference/
LOCATION:San Diego\, CA
ORGANIZER;CN="MarketsandMarkets Research Private Ltd.":MAILTO:suraj.waghmare@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200206
DTEND;VALUE=DATE:20200208
DTSTAMP:20260515T051658
CREATED:20191031T101817Z
LAST-MODIFIED:20191031T101817Z
UID:23125-1580947200-1581119999@www.pharmajournalist.com
SUMMARY:5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference
DESCRIPTION:The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 6th – 7th February 2020 in San Diego\, CA would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers\, Precision Medicine and Big Data. Regarding commercialization of biomarkers\, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers. \n \nTo learn more about 5th Annual Biomarker and Companion Diagnostics Conference click here
URL:https://www.pharmajournalist.com/event/5th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-conference/
LOCATION:MA
ORGANIZER;CN="MarketsandMarkets Research Private Ltd.":MAILTO:Shardul.oza@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200206
DTEND;VALUE=DATE:20200208
DTSTAMP:20260515T051658
CREATED:20191031T102512Z
LAST-MODIFIED:20191031T104231Z
UID:23129-1580947200-1581119999@www.pharmajournalist.com
SUMMARY:MarketsandMarkets Gen-Next Probiotics and Microbiome Congress
DESCRIPTION:What are the essentials being missed out on? What is the real role of probiotics strains\, prebiotics and symbiotic in influencing a health? How do you standardize microbiome analysis? \nWitness the major breakthroughs of microbiome\, probiotics and prebiotics research along with their applications pertaining to challenges like medicinal data interpretation\, investment and regulatory hurdles faced by the practitioners. The intersection between emerging technology and discovery with the context of consumer interest. Detect the non-identified dysbiosis\, to discover the potential areas under study for investments in Gut and Skin microbiome and its role as a diagnostic tool of pharmaceutical discovery. \n \nJoin us at Gen-Next Probiotics and Microbiome Congress\, 2020 to network with biotech\, pharma\, academicians and investors to exchange views and observe the most ingenious research and technologies. Understand what’s happening. Witness the amalgamation of study focused on pharmaceutical and medicinal approaches of probiotics and the nutraceutical and consumer approaches along with the role of microbiome in clinical applications and preventative medicine. \nTo learn more about MarketsandMarkets Gen-Next Probiotics and Microbiome Congress click here
URL:https://www.pharmajournalist.com/event/marketsandmarkets-gen-next-probiotics-and-microbiome-congress/
LOCATION:San Diego\, CA
ORGANIZER;CN="MarketsandMarkets Research Private Ltd.":MAILTO:suraj.waghmare@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200217
DTEND;VALUE=DATE:20200219
DTSTAMP:20260515T051658
CREATED:20200109T074622Z
LAST-MODIFIED:20200109T074622Z
UID:23582-1581897600-1582070399@www.pharmajournalist.com
SUMMARY:Smartlab Exchange Europe
DESCRIPTION:The Smartlab Exchange is an invitation-only meeting bringing together 70 of the most senior lab leaders from across Europe\, plus a number of hand-selected solution providers for two days of one-to-one business meetings\, benchmarking\, discussions and networking. \n \nKey themes include: \n✓ Devising a Roadmap to Success for an Agile\, Adaptable\, Digitised Lab\n✓ Leveraging Big Data Analytics and Informatics\n✓ Embedding a Culture of Collaboration and Innovation\n✓ Enhancing Visibility Across Existing Systems/Processes and Integrate Emerging Technologies\n✓ Implementing Methods to Safeguard Data Integrity and Uphold Regulatory Compliance \n96% of our attendees would recommend our event \n“I got more out of one day at Smartlab than a normal day at another conference.” –  R&D IS Program Manager\, Biomerieux \nBelow are some of the 20+ presentations and interactive sessions we have in store: \n\nNovartis – Exploring Data Visualisation Software To Increase The Accuracy Of Your Predictions\nRoche – Connecting Your Instruments For Easy Data Access And Analysis Across Your Lab\nJanssen – The Lab Of The Future: Predicting How The Lab Will Develop In the Next 5 Years\nUCB – Developing Your Data Capture Process For Increased Efficiency\n\nCheck out the full agenda here: http://bit.ly/2T75ps7
URL:https://www.pharmajournalist.com/event/smartlab-exchange-europe/
LOCATION:Hotel Palace Berlin\, Germany
ORGANIZER;CN="IQPC":MAILTO:info@exchangeevents.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200218
DTEND;VALUE=DATE:20200221
DTSTAMP:20260515T051658
CREATED:20191017T094701Z
LAST-MODIFIED:20191017T094701Z
UID:22911-1581984000-1582243199@www.pharmajournalist.com
SUMMARY:Disposable Solutions for Bio Manufacturing
DESCRIPTION:Now in it’s 12th year\, the 2020 Disposable Solutions for Biomanufacturing Forum is the only global forum that focuses on the use of disposable products and single use systems in biomanufacturing. Our attendees will be guided through their journey and understand how they can run 100% disposable sites and scale their manufacturing capabilities with our newly designed program focused on implementation\, systems management and future technology. \n \nThe three packed days will consist of case studies and interactive sessions to identify new technologies\, determine how to approach automated systems\, transition to continuous processes and learn how to implement best practice in system testing & life cycle management! \nTo learn more about Disposable Solutions for Bio Manufacturing and to register online\, visit http://bit.ly/2Mp6lEs
URL:https://www.pharmajournalist.com/event/disposable-solutions-for-bio-manufacturing/
LOCATION:Leonardo Royal Hotel Berlin Alexanderplatz\, Berlin\, Germany\, Germany
ORGANIZER;CN="IQPC":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200219
DTEND;VALUE=DATE:20200221
DTSTAMP:20260515T051658
CREATED:20171019T063951Z
LAST-MODIFIED:20191004T082421Z
UID:3496-1582070400-1582243199@www.pharmajournalist.com
SUMMARY:RNA Therapeutics
DESCRIPTION:SMi Group are pleased to present the 11th Annual RNA Therapeutics Conference and Focus Day in London on February 18th – 20th 2020. \nThe field of RNA therapeutics is rapidly expanding\, and the potential for using RNA drugs for personalised medicines and immunotherapy\, as well as to address genetic\, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come. \n \nThe event will focus on the latest research and developments on delivery system technologies that aim to tackle more difficult targets within the human body. This overarching topic warrants high focus and therefore\, for the first time in the series\, introduce a focus day on Oligonucletide Delivery Systems. The main conference will focus on current developments in the area of mRNA therapeutics in immunotherapy and vaccination. \nNEW FOR 2020: RNA Therapeutics Focus Day – Oligonucleotide Delivery Systems \nIntroducing the only RNA therapeutics conference to hold a full day exploring alternatives to oligonucleotide delivery systems. The global antisense and RNA therapeutics market is expected to expand at a compound annual growth rate (CAGR) of 8.6% between 2019 and 2025\, projected to reach $1.81 billion\, this focus day will assess the growing need for research and development of novel delivery approaches to expand the current delivery methods in today’s market. \nHow will you benefit? \n\nDiscuss the innovations in oligonucleotide delivery systems\nExplore the latest developments in RNA delivery agents and RNA-based therapeutics\nLearn from case studies on clinical developments with leading RNA therapeutics companies and regulatory bodies\nRevisit the challenges for clinical translation of RNA-based therapeutics\nEvaluate the applications of RNA-based drugs for modulation of gene and protein expression\, and genome editing\nGain an expert view on new and upcoming regulatory updates and industry implications\n\nNetwork and learn from leading professionals such as: \nCHAIR FOR 2020 \nHeinrich Haas\, VP RNA Formulation and Drug Delivery\, BioNTech \nFEATURED SPEAKERS INCLUDE: \n\nShalini Andersson\, Chief Scientist New Therapeutic Modalities\, AstraZeneca\nChristian Plank\, CTO\, Ethris\nSteve Pascolo\, Founder and CEO\, Miescher Pharma\nKirsty Wydenbach\, Deputy Unit Manager\, Clinical Trials Unit\, MhRA\nSteven Powell\, CEO\, eTheRNA\nSimon Newman\, CSO\, Nanogenics\nChristiane Niederlaender\, Director\, AMBR Consulting and Formerly\,\nQuality Assessor\, Biologicals\, MhRA\nKlaus Giese\, CEO\, Pantherna Therapeutics\nDavid Blakey\, CSO\, MiNA Therapeutics\nJeffrey Ulmer\, Head Preclinical R&D\, GSK\n\nFor more information and to register\, visit: www.therapeutics-rna.com/pjwb  \nEarly-Bird Rates \nREGISTER BY 31ST OCTOBER TO SAVE £400 \nREGISTER BY 29Th NOVEMBER TO SAVE £200 \nREGISTER BY 13Th DECEMBER TO SAVE £100 \nSocial Media Handles \nFollow us on LinkedIn ‘SMi Pharma’\, Twitter @SMiPharm and use #SMiRNA
URL:https://www.pharmajournalist.com/event/rna-therapeutics/
LOCATION:London\, UK\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:nhoward@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200219
DTEND;VALUE=DATE:20200221
DTSTAMP:20260515T051658
CREATED:20191015T105531Z
LAST-MODIFIED:20191015T105531Z
UID:22854-1582070400-1582243199@www.pharmajournalist.com
SUMMARY:SMi’s 4th Annual 3D Cell Culture
DESCRIPTION:CHAIRED BY:\nPhilip Hewitt\, UK and Eurotox Registered Toxicologist\, Global Head of Early Investigative Toxicology\, Merck Healthcare KGaA\nStefan Przyborski\, Professor of Cell Technology\, Durham university \nDevelopment and application of human organs and tissues in vitro\nOver the past few years\, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues\, drug discovery\, predictivity and validation\, and safety and toxicity.\n\nSMi’s 3D Cell Culture Conference will explore advances of organ and lab-on-a-chip\, microphysiological systems\, applications of technology and case studies\, imaging\, high throughput screening and advances in 3D cell culture models which make up core components within the 3D Cell Culture field. \nBioprinting has become increasingly efficient and accurate in building in vitro tissue models with the potential to provide pathologically relevant responses and model human disease mechanisms. Bio-printed structures yield phenotypic endpoints that are comparable with clinical studies and can provide a realistic prediction of clinical efficacy. The use of bioprinting is growing in big pharma companies as an alternative to organ-on-a-chip systems. \nFor the first time ever the NEW 3D Bioprinting Focus Day on 18 February 2020 will explore case studies from big pharma\, biotech’s and academia exploring how bioprinting is being used in industry highlighting projects looking at stem cell therapy\, drug screening and extracellular matrix scaffolds. \nEvent Hashtag: #SMi3DCellCulture \nFEATURED SPEAKERS INCLUDE: \n\nLeonard Both\, Senior Quality Assessor\, Biologicals/Biotechnology Unit\, MHRA\nVeronique Barban\, Expert Virology\, Research and Nonclinical Safety Department\, Sanofi Pasteur\nSimone Stahl\, Associate Principal Scientist\, ADME Sciences\, Clinical Pharmacology and Safety Sciences\, AstraZeneca\nWendy Rowan\, Scientific Director\, Novel Human Genetics Research Unit\, GSK\nJason Ekert\, Head of Complex In Vitro Models\, GSK\nSamuel Jackson\, Programme Manager\, Disease Models Efficacy and Safety Pharmacology\, NC3RS\n\nKEY TOPICS FOR 2019 INCLUDE: \n\nLearn from leading pharma companies to benchmark against their applications of 3D technology\nExplore case studies of 3D cell culture\, high throughput screening\, imaging and microphysiological systems in industry\nHear about the latest technology advances allowing 3D bioprinting to revolutionise in vitro models\nDiscuss organ-on-chip technologies and their applications to replace the use of animals in pharmaceutical research\nParticipate in a panel discussion on adopting new technologies for 3D models\n\nView the full agenda: http://www.3d-cellculture.com/PJWL \nWHO SHOULD ATTEND? \nBiotech / Pharma Companies – Team Leader\, Junior Principle investigator\, Cell and Molecular Scientist\, Chief Scientific Officer\, Deputy Director\, Manager\, Founder\, CEO\, Head\, Director\, Programme Manager\, Lab Head\, Toxicologist \nAcademia Professor – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering \nSolution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer \nEARLY BIRD-RATES \n\nREGISTER BY 31ST OCTOBER AND SAVE £400\nREGISTER BY 29TH NOVEMBER AND SAVE £200\nREGISTER BY 13TH DECEMBER AND SAVE £100
URL:https://www.pharmajournalist.com/event/smis-4th-annual-3d-cell-culture/
LOCATION:Copthorne Tara Hotel\, London\, UK\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200224
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T051658
CREATED:20191016T074751Z
LAST-MODIFIED:20191017T085729Z
UID:22867-1582502400-1582847999@www.pharmajournalist.com
SUMMARY:CAR-TCR Europe Summit
DESCRIPTION:With CAR-T therapies on the cusp of achieving global approval\, there are still many bottlenecks that are preventing this from becoming the ‘sell-out’ therapy that the field had hoped for. The CAR-TCR Europe Summit will unravel the technical challenges across translation\, scale and delivery to provide your team with the platform to learn\, collaborate and gain actionable insights to advance your therapy for clinical and commercial success. \nThis focused agenda will delve into the technical bottlenecks encountered in every stage of the CAR-TCR drug development cycle\, providing a comprehensive analysis across 3 tracks including: Translational\, Manufacturing & Clinical \nTo learn more about CAR-TCR Europe Summit and to register online\, visit https://ter.li/9iuqer
URL:https://www.pharmajournalist.com/event/car-tcr-europe-summit/
LOCATION:Novotel London West\, Hammersmith\, London\, W6 8DR
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200225
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T051658
CREATED:20191016T073714Z
LAST-MODIFIED:20191017T085556Z
UID:22862-1582588800-1582847999@www.pharmajournalist.com
SUMMARY:3rd Antigen Specific Immune Tolerance Summit
DESCRIPTION:Translating Emerging Antigen Specific Immune Tolerance Approaches for Therapeutic Applications \nAccelerate the progression of ethical and effective antigen specific immunotherapies through the clinic\, optimize the discovery of novel targets and explore novel therapeutic approaches harnessing combination therapies. \n \nBuilding on the success of the 2019 meeting\, the 3rd Antigen Specific Immune Tolerance Summit (ASIT) returns to Boston on February 25-27\, 2020. The meeting will bring together industry representatives from the fields of autoimmunity\, allergy\, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies\, ASIT 2020 is the only antigen specific summit offering thought leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development. \n\nHear from and engage with a world-class speaking faculty made up of 26 industry representatives including Novo Nordisk\, Pfizer\, Merck\, Eli Lilly\, ITN & FDA\nExplore cross learning opportunities from parallel fields tackling immune tolerance and better understand the fundamental mechanisms that lie behind tolerance induction\nEngage with and immerse yourself within a learning journey across three conference days\, tackling all elements of drug development from discovery to clinical development\nGain practical insight from those describing recent clinical trials and determine what mechanisms lie behind successful and unsuccessful clinical trials\nEmploy novel therapeutics in combination with antigen specific immunotherapies and drive the progression of drug development towards the clinic\nTake advantage of intimate networking opportunities with key opinion leaders from large pharma\, biotech and academia through discursive and engaging platforms that spark conversation and debate\n\nTo learn more about 3rd Antigen Specific Immune Tolerance Summit and to register online\, visit https://ter.li/rp07a3
URL:https://www.pharmajournalist.com/event/3rd-antigen-specific-immune-tolerance-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200225
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T051658
CREATED:20191215T123515Z
LAST-MODIFIED:20191215T123645Z
UID:23340-1582588800-1582847999@www.pharmajournalist.com
SUMMARY:RAS- Targeted Drug Discovery Summit Europe
DESCRIPTION:After three decades of trial and error to target the driver of 30% of all diagnosed cancers\, scientists are finally making meaningful clinical progression to target the cancer master switch\, the RAS family of proteins. \n \nThe RAS- Targeted Drug Discovery Summit Europe is the only industry-led and translational focused platform dedicated to bringing you innovative anti-RAS drug discovery science\, capturing the most pioneering data\, thought-provoking insights and practical lessons learned\, enabling you to maximise the clinical therapeutic window of your anti-RAS candidate. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins\, gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic. Hear from the likes of Boehringer Ingelheim\, Sanofi\, Bayer\, Francis Crick Institute\, PhoreMost\, Allinky Biopharma\, Elicio Therapeutics\, Oblique Therapeutics\, Onconova Therapeutics and Revolution Medicines. Visit the website to see the full speaker line-up\, what will be discussed\, pricing and ticket options: https://ter.li/8qb2rr.
URL:https://www.pharmajournalist.com/event/ras-targeted-drug-discovery-summit-europe/
LOCATION:Hilton Vienna Plaza\, Schottenring 11\, Vienna\, A - 1010\, Austria
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200225
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T051659
CREATED:20200110T081422Z
LAST-MODIFIED:20200110T081422Z
UID:23647-1582588800-1582847999@www.pharmajournalist.com
SUMMARY:8th Neurodegenerative Drug Development Summit
DESCRIPTION:Returning to Boston in February 2020 is the 8th Neurodegenerative Drug Development Summit\, previously World CNS. \nDespite the lack of clinical trial success\, new investments are being made in forward-thinking biotechs\, digital and blood-based biomarker technologies are advancing\, new targets are emerging\, and gene therapy is taking the limelight. \nThe Neurodegenerative Drug Development Summit will unite industry stakeholders to learn how to overcome their translational challenges\, share their progress and network for future collaborations to accelerate the development of successful neurodegenerative therapeutics. \nDon’t miss your opportunity to join over 150 fellow CNS experts from Biogen\, AbbVie\, Sanofi and more\, and immerse yourself in the neurodegenerative community to help refresh the neurodegenerative approach and challenge traditional thinking to advance clinical progress.
URL:https://www.pharmajournalist.com/event/8th-neurodegenerative-drug-development-summit/
LOCATION:Hyatt Regency Boston\, 1 Avenue de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200226
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T051659
CREATED:20200217T092303Z
LAST-MODIFIED:20200217T092639Z
UID:24192-1582675200-1582847999@www.pharmajournalist.com
SUMMARY:21st Pharmacovigilance 2020
DESCRIPTION:“Latest developments in pharmacovigilance\, drug safety and RMP” \n21st Pharmacovigilance 2020 event keeps an immersed eye on discussion of critical topics in PV domain\, which capture influence of emerging technologies like AI\, IoT\, Big Data. Not merely that\, we have exciting surprise activities which will help you to interact more with your peers. This will be surely an exciting event wherein you could get chance to meet big industry gems. Let’s gather to shape the industry with your magnificent ideas. \n \nSPONSORS: \n\nCovance\nBrookwood Global\n\nWe also have more sponsorship opportunities available for the event\, which gives you an opportunity to sponsor/speak/exhibit/Booth/Stall and create brand awareness. In addition\, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. \nDELEGATE REGISTRATION: \nIn order to register please contact us on Email: kavitha@virtueinsight.co.in   \n1 Delegate @ £1299 + VAT \n3 Delegates @ £2598 + VAT \nGet more from the event\, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time\, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
URL:https://www.pharmajournalist.com/event/21st-pharmacovigilance-2020/
LOCATION:Pestana Chelsea Bridge Hotel\, London\, United Kingdom
ORGANIZER;CN="Virtue Insight":MAILTO:kavitha@virtueinsight.co.in
END:VEVENT
END:VCALENDAR